We focus on developing life science companies which are built to succeed. We’re excited to have founding investor CIC support us and our emerging world class businesses.
Jason Mellad, CEO
Daniel Rooke, COO
CIC’s support has enabled Riverlane to become a globally leading software and algorithm company in the rapidly emerging field of quantum computing
Leonie Mueck, Chief Product Officer
Steve Brierley, CEO and Founder
Bek Simmons, Chief Operating Officer
PetMedix develops antibody therapeutics for dogs and cats. CIC’s investment enables us to accelerate our program to make the drugs our pets need and deserve
Tom Weaver, CEO
Jolyon Martin, Head of Business Development
CIC’s investment has helped us in our ambition to develop a transformational medicine for the treatment of pulmonary artery hypertension
Wei Li, Co-Founder
We're enabling the rapid deployment of machine learning models so organisations can tackle their most important challenges. CIC's deep tech expertise and commercial acumen is the ideal support for our mission.
Alex Housley, Founder and CEO
Clive Cox, CTO
CIC immediately recognised the disruptive potential of AudioTelligence’s audio processing technology. They were the ideal founding partner for AudioTelligence, bringing strong commercial and operational experience.
Ken Roberts, CEO
CIC’s backing enables us to compete on the global stage to realise our bold vision of transforming healthcare through decentralisation
Ralph Lamble, Chief Development Officer
Harry Lamble, CEO
We are building the world’s smartest video platform. CIC has been a rock steady partner who understands the challenges and needs of a company with global ambitions
Charlie Horell, CEO
CIC's support for our vision allowed us to develop world-leading non-invasive diagnostic tests for cancer using liquid biopsies.
Nitzan Rosenfeld, Co-Founder and Chief Scientific Officer
CIC’s investment will enable us to grow the PolyProx team and further develop our technology. Our platform harnesses the cell’s natural protein degradation machineries, allowing access to hard-to-drug targets.
Laura Itzhaki, Chief Scientific Officer
Undo's platform saves its customers large sums of money by significantly reducing MTTR of software failures. CIC has been instrumental in the scaling of our commercial operations.
Dr Greg Law, Co-founder & CTO
Exvastat is developing a pioneering new treatment for Acute Respiratory Distress Syndrome. CIC has strongly supported us with advocacy as well as money.
David Cavalla, Executive Director
CIC’s approach is a great fit with PragmatIC’s unique flexible electronics platform and vision towards trillions of smart objects
Scott White, CEO
We are harnessing cutting-edge RNA epigenetic enzyme technology to develop first in class drugs. CIC’s expertise and collaborative approach has been vital to the development of our company.
Tony Kouzarides, Founder & Director Eric Miska, Founder & Director
Our revolutionary sound recognition technology brings contextual AI to machines. CIC has deep domain expertise and relationships which are invaluable
Chris Mitchell, CEO & Founder
Secondmind optimizes the most important activity at any company: decision-making. CIC is one of our most trusted and valuable partners
Vishal Chatrath, Co-Founder
We believe in building sustainable collaborative partnerships. CIC has been a constant, constructive investor during our rapid growth
Martin Frost, Co-Founder
Paul Roberts, Co-Founder
Keith Marshall, Co-Founder
GeoSpock are creating an operating system for the physical world in which CIC have been a trusted partner in helping us to achieve success
Steve Marsh, Founder, CEO & CTO
CIC have extensive experience investing in the digital transformation of global energy systems and saw the potential for Origami’s technology platform to lead this transformation in the UK and beyond
Peter Bance, CEO
We enable visionaries to build global, category-leading companies
Cambridge Innovation Capital backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem.